381 related articles for article (PubMed ID: 15339971)
1. Multiparametric flow cytometric analysis of inter-patient variation in STAT1 phosphorylation following interferon Alfa immunotherapy.
Lesinski GB; Kondadasula SV; Crespin T; Shen L; Kendra K; Walker M; Carson WE
J Natl Cancer Inst; 2004 Sep; 96(17):1331-42. PubMed ID: 15339971
[TBL] [Abstract][Full Text] [Related]
2. Multiparametric flow cytometric analysis of signal transducer and activator of transcription 5 phosphorylation in immune cell subsets in vitro and following interleukin-2 immunotherapy.
Varker KA; Kondadasula SV; Go MR; Lesinski GB; Ghosh-Berkebile R; Lehman A; Monk JP; Olencki T; Kendra K; Carson WE
Clin Cancer Res; 2006 Oct; 12(19):5850-8. PubMed ID: 17020993
[TBL] [Abstract][Full Text] [Related]
3. IFN-alpha-2b-induced signal transduction and gene regulation in patient peripheral blood mononuclear cells is not enhanced by a dose increase from 5 to 10 megaunits/m2.
Zimmerer JM; Lehman AM; Ruppert AS; Noble CW; Olencki T; Walker MJ; Kendra K; Carson WE
Clin Cancer Res; 2008 Mar; 14(5):1438-45. PubMed ID: 18316567
[TBL] [Abstract][Full Text] [Related]
4. Melanoma cells exhibit variable signal transducer and activator of transcription 1 phosphorylation and a reduced response to IFN-alpha compared with immune effector cells.
Lesinski GB; Trefry J; Brasdovich M; Kondadasula SV; Sackey K; Zimmerer JM; Chaudhury AR; Yu L; Zhang X; Crespin TR; Walker MJ; Carson WE
Clin Cancer Res; 2007 Sep; 13(17):5010-9. PubMed ID: 17785551
[TBL] [Abstract][Full Text] [Related]
5. Clinical and immunologic effects of subcutaneously administered interleukin-12 and interferon alfa-2b: phase I trial of patients with metastatic renal cell carcinoma or malignant melanoma.
Alatrash G; Hutson TE; Molto L; Richmond A; Nemec C; Mekhail T; Elson P; Tannenbaum C; Olencki T; Finke J; Bukowski RM
J Clin Oncol; 2004 Jul; 22(14):2891-900. PubMed ID: 15254058
[TBL] [Abstract][Full Text] [Related]
6. The antitumor effects of interferon-alpha are maintained in mice challenged with a STAT1-deficient murine melanoma cell line.
Badgwell B; Lesinski GB; Magro C; Abood G; Skaf A; Carson W
J Surg Res; 2004 Jan; 116(1):129-36. PubMed ID: 14732359
[TBL] [Abstract][Full Text] [Related]
7. Interferon alpha and CPG oligodeoxynucleotides elicit additive immunostimulatory and antitumor effects.
Brown L; Roda J; Terrell C; Chaudhury AR; Crespin T; Carson WE; Lesinski GB
Surgery; 2006 Aug; 140(2):297-306. PubMed ID: 16904983
[TBL] [Abstract][Full Text] [Related]
8. Phase I study of the sequential combination of interleukin-12 and interferon alfa-2b in advanced cancer: evidence for modulation of interferon signaling pathways by interleukin-12.
Eisenbeis CF; Lesinski GB; Anghelina M; Parihar R; Valentino D; Liu J; Nadella P; Sundaram P; Young DC; Sznol M; Walker MJ; Carson WE
J Clin Oncol; 2005 Dec; 23(34):8835-44. PubMed ID: 16314644
[TBL] [Abstract][Full Text] [Related]
9. Regulatory T cell frequency in patients with melanoma with different disease stage and course, and modulating effects of high-dose interferon-alpha 2b treatment.
Ascierto PA; Napolitano M; Celentano E; Simeone E; Gentilcore G; Daponte A; Capone M; Caracò C; Calemma R; Beneduce G; Cerrone M; De Rosa V; Palmieri G; Castello G; Kirkwood JM; Marincola FM; Mozzillo N
J Transl Med; 2010 Aug; 8():76. PubMed ID: 20712892
[TBL] [Abstract][Full Text] [Related]
10. Defective STAT1 activation associated with impaired IFN-γ production in NK and T lymphocytes from metastatic melanoma patients treated with IL-2.
Sim GC; Wu S; Jin L; Hwu P; Radvanyi LG
Oncotarget; 2016 Jun; 7(24):36074-36091. PubMed ID: 27153543
[TBL] [Abstract][Full Text] [Related]
11. Interferon-alpha-induced activation of signal transducer and activator of transcription proteins in malignant melanoma.
Carson WE
Clin Cancer Res; 1998 Sep; 4(9):2219-28. PubMed ID: 9748142
[TBL] [Abstract][Full Text] [Related]
12. The expression of cytotoxic mediators is altered in mononuclear cells of patients with melanoma and increased by interferon-alpha treatment.
Guillot B; Portalès P; Thanh AD; Merlet S; Dereure O; Clot J; Corbeau P
Br J Dermatol; 2005 Apr; 152(4):690-6. PubMed ID: 15840100
[TBL] [Abstract][Full Text] [Related]
13. The Raf Kinase Inhibitor Sorafenib Inhibits JAK-STAT Signal Transduction in Human Immune Cells.
Martin del Campo SE; Levine KM; Mundy-Bosse BL; Grignol VP; Fairchild ET; Campbell AR; Trikha P; Mace TA; Paul BK; Jaime-Ramirez AC; Markowitz J; Kondadasula SV; Guenterberg KD; McClory S; Karpa VI; Pan X; Olencki TE; Monk JP; Mortazavi A; Tridandapani S; Lesinski GB; Byrd JC; Caligiuri MA; Shah MH; Carson WE
J Immunol; 2015 Sep; 195(5):1995-2005. PubMed ID: 26238487
[TBL] [Abstract][Full Text] [Related]
14. The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse.
Lesinski GB; Anghelina M; Zimmerer J; Bakalakos T; Badgwell B; Parihar R; Hu Y; Becknell B; Abood G; Chaudhury AR; Magro C; Durbin J; Carson WE
J Clin Invest; 2003 Jul; 112(2):170-80. PubMed ID: 12865406
[TBL] [Abstract][Full Text] [Related]
15. Gene expression profiling reveals similarities between the in vitro and in vivo responses of immune effector cells to IFN-alpha.
Zimmerer JM; Lesinski GB; Ruppert AS; Radmacher MD; Noble C; Kendra K; Walker MJ; Carson WE
Clin Cancer Res; 2008 Sep; 14(18):5900-6. PubMed ID: 18794103
[TBL] [Abstract][Full Text] [Related]
16. Reduction in p48-ISGFgamma levels confers resistance to interferon-alpha2a in MHCC97 cells.
Wu WZ; Sun HC; Gao YQ; Li Y; Wang L; Zhou K; Liu KD; Iliakis G; Tang ZY
Oncology; 2004; 67(5-6):428-40. PubMed ID: 15714000
[TBL] [Abstract][Full Text] [Related]
17. Stat1 and Stat2 but not Stat3 arbitrate contradictory growth signals elicited by alpha/beta interferon in T lymphocytes.
Gimeno R; Lee CK; Schindler C; Levy DE
Mol Cell Biol; 2005 Jul; 25(13):5456-65. PubMed ID: 15964802
[TBL] [Abstract][Full Text] [Related]
18. IL-12 pretreatments enhance IFN-alpha-induced Janus kinase-STAT signaling and potentiate the antitumor effects of IFN-alpha in a murine model of malignant melanoma.
Lesinski GB; Badgwell B; Zimmerer J; Crespin T; Hu Y; Abood G; Carson WE
J Immunol; 2004 Jun; 172(12):7368-76. PubMed ID: 15187113
[TBL] [Abstract][Full Text] [Related]
19. Down-regulation of the interferon signaling pathway in T lymphocytes from patients with metastatic melanoma.
Critchley-Thorne RJ; Yan N; Nacu S; Weber J; Holmes SP; Lee PP
PLoS Med; 2007 May; 4(5):e176. PubMed ID: 17488182
[TBL] [Abstract][Full Text] [Related]
20. Expression of STAT1 and STAT2 in malignant melanoma does not correlate with response to interferon-alpha adjuvant therapy.
Lesinski GB; Valentino D; Hade EM; Jones S; Magro C; Chaudhury AR; Walker MJ; Carson WE
Cancer Immunol Immunother; 2005 Sep; 54(9):815-25. PubMed ID: 15668815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
